Why Batch Documentation Matters When Importing Indian Branded Medicines

In pharmaceutical trade, the batch is the fundamental unit of accountability. Every tablet in a box of branded medicine came from a specific, identifiable production run — with defined raw materials, manufacturing parameters, quality tests, and release decisions. Batch documentation is the paper trail that links the product in your hands to that production run.

For importers of branded Indian medicines, requiring and reviewing proper batch documentation is a non-negotiable quality practice — not a bureaucratic formality.

---

The Traceability Chain

Pharmaceutical batch documentation creates a traceability chain:

The batch number is the thread running through this entire chain. With a batch number, an auditor or regulatory authority can trace a specific product unit back through every step of its production.

---

The Documents an Importer Should Require

Certificate of Analysis (CoA) — Mandatory

As discussed in detail in our CoA explainer post, the CoA confirms that the specific batch has been tested and meets its specification. This is the minimum document for every pharmaceutical import.

Manufacturer's GMP Certificate — Required for Registration

The manufacturer's current GMP certificate confirms the facility producing your product is operating under a recognised quality system. For product registration in most importing countries, this is a required document.

Verify: - The GMP certificate is current (within its validity period) - The facility address matches the manufacturer address on the product label and CoA - The certificate covers the relevant product type (oral solids, injectables, etc.)

Certificate of Conformance / Declaration of Conformity

Some buyers, particularly those in regulated markets or institutional procurement, request a Certificate of Conformance — a statement from the manufacturer that the batch was produced in accordance with applicable GMP standards and meets its specification. This is distinct from the CoA (which states test results) — it is a broader compliance declaration.

Batch Manufacturing Record Summary (for higher-risk procurement)

For high-value or high-risk products (oncology, narrow therapeutic index drugs, injectables), some sophisticated buyers request a Batch Manufacturing Record (BMR) summary — not the full BMR (which is proprietary), but a summary confirming key production parameters were met.

This level of documentation request is more typical in institutional or regulated-market procurement than in standard commercial import.

---

For Branded Medicines Specifically

Branded medicines (ethical channel products) come with the additional quality assurance of the brand manufacturer's QA system. The manufacturer's brand reputation is on the line with every batch — which creates commercial incentive for quality consistency beyond just regulatory compliance.

When importing branded Indian medicines, also confirm: - Manufacturer authorisation: That the trader/exporter is an authorised distributor or stockist for the brand — not sourcing grey-market product - Batch traceability back to the brand manufacturer: The CoA should be on the brand manufacturer's letterhead, not a secondary party's

---

When to Escalate a Documentation Concern

If you receive: - A CoA that cannot be confirmed as authentic (no way to contact the manufacturer directly for verification) - A batch number that does not match the product packaging - Results that look identical across multiple batches (potential indicator of fabrication) - A CoA on a trader's letterhead rather than the manufacturer's

Stop. Do not distribute the product until the documentation issue is resolved. Contact your supplier for original documentation from the manufacturer, and if the issue cannot be resolved satisfactorily, contact the manufacturer directly or involve your country's regulatory authority.

---